Hailey Gilmore
@liminaluminous.bsky.social
Psychedelic research consultant with 15 years clinical trial management and medical affairs experience.
Check out my services and connect directly at luminousrcs.com
Check out my services and connect directly at luminousrcs.com
Dropping in to remind you that this story exists, and it's already 5 years old.
"What vision do you hold in your heart for a psychedelic future?
What will you do now, while you can, to see that it is realized?"
"What vision do you hold in your heart for a psychedelic future?
What will you do now, while you can, to see that it is realized?"
We Will Call It Pala
A Story For The Psychedelic Movement
hereandnowstudios.com
January 7, 2025 at 5:35 AM
Dropping in to remind you that this story exists, and it's already 5 years old.
"What vision do you hold in your heart for a psychedelic future?
What will you do now, while you can, to see that it is realized?"
"What vision do you hold in your heart for a psychedelic future?
What will you do now, while you can, to see that it is realized?"
Great 2 see both #APA s entering the #psychedelic chat. All hands welcome! Beyond funding, quality trials, & meaningful data, there are policy, process, & infrastructure to build 4 PAT coverage, access, & rollout, if approved. I recently spoke w/ Zach over at #TheTripReport abt these complexities:
#38 Hailey Gilmore: The Complexity of Psychedelic Science
Welcome back to The Trip Report Podcast, a production of Beckley Waves.
www.thetripreport.com
January 7, 2025 at 4:02 AM
Great 2 see both #APA s entering the #psychedelic chat. All hands welcome! Beyond funding, quality trials, & meaningful data, there are policy, process, & infrastructure to build 4 PAT coverage, access, & rollout, if approved. I recently spoke w/ Zach over at #TheTripReport abt these complexities:
My 2023 reads (not pictured: Cloud Cuckoo Land (audio) on my 2nd Xcountry move of the year & the dozens of academic papers we all do for work). 2024 goal: more fiction! And - 1 book/month, so a 25% ⬆️. I used to have multiple going at a time, hoping focusing on 1 will help completion rate #tsundoku
January 4, 2025 at 6:32 PM
My 2023 reads (not pictured: Cloud Cuckoo Land (audio) on my 2nd Xcountry move of the year & the dozens of academic papers we all do for work). 2024 goal: more fiction! And - 1 book/month, so a 25% ⬆️. I used to have multiple going at a time, hoping focusing on 1 will help completion rate #tsundoku
1. Masters level epi/biostat & veteran clin ops mgr from the HIV treatment/prevention space using skillset to ⬆️rigor & reach of psychedelic trials-formerly at Lykos (IIT program, MSL), now consultant
2. Sorry-under NDA :) but here: luminousrcs.com
3. Finally watching "What we do in the shadows"!
2. Sorry-under NDA :) but here: luminousrcs.com
3. Finally watching "What we do in the shadows"!
November 18, 2024 at 5:27 PM
1. Masters level epi/biostat & veteran clin ops mgr from the HIV treatment/prevention space using skillset to ⬆️rigor & reach of psychedelic trials-formerly at Lykos (IIT program, MSL), now consultant
2. Sorry-under NDA :) but here: luminousrcs.com
3. Finally watching "What we do in the shadows"!
2. Sorry-under NDA :) but here: luminousrcs.com
3. Finally watching "What we do in the shadows"!
Reposted by Hailey Gilmore
Cybin Shares Positive 12-month Ph 2 Data for its Deiterated Psilocin Candidate, CYB003, in Major Depressive Disorder (MDD)
100% of patients responders and 71% in remission at the 12-month mark.
www.businesswire.com/news/home/20...
100% of patients responders and 71% in remission at the 12-month mark.
www.businesswire.com/news/home/20...
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revoluti
www.businesswire.com
November 18, 2024 at 3:33 PM
Cybin Shares Positive 12-month Ph 2 Data for its Deiterated Psilocin Candidate, CYB003, in Major Depressive Disorder (MDD)
100% of patients responders and 71% in remission at the 12-month mark.
www.businesswire.com/news/home/20...
100% of patients responders and 71% in remission at the 12-month mark.
www.businesswire.com/news/home/20...